Palareti G, Testa S, Legnani C, Paoletti O, et al. The use of reduced DOAC doses in atrial fibrillation patients does not always lead to good anticoagulation levels and avoid adverse events. Int J Cardiol 2024 Aug 24:132484. doi: 10.1016/j.ijcard.2024.132484.
PMID: 39187070